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E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 53K-Ras and Src. The present study was performed to obtain first
evidence for a prognostic relevance of transcription factors differ-
entially bound to the u-PAR-promoter, and their molecular induc-
ers, in colorectal cancer.
Patients and Methods: Tumors/normal tissues of prospectively
followed 92 patients were analyzed for Src-activity, K-ras-muta-
tions, and transcription factor binding to both u-PAR-promoter
motifs (in vivo-gelshift, kinase-assay, PCR).
Results: Kaplan–Meier analysis (Mantel-Cox) showed a signifi-
cant correlation between elevated binding of Sp1/Sp3 to region -
152/-135 (p = 0.002, p = 0.006), the combinations of Sp1/AP-2 and
Sp1/AP-1 binding to both motifs (p = 0.010, p = 0.005), and Sp1-
binding/high Src-protein in tumors (p < 0.001), with poor survival.
Survival risk increased with the number of bound transcription
factors, the binding of three transcription factors to both u-PAR-
promoter motifs defining a high risk group for survival
(p = 0.021). In multivariate analysis, elevated binding of Sp1, or
combinations of Sp1/AP-2-binding, Sp1/AP-1-binding, or Sp1-
binding/high Src, were new and independent prognostic parame-
ters besides surgical curability, and UICC. A first molecular staging
model (CART) could define new high-risk groups from transcrip-
tion factors bound to specific promoter motifs.
Conclusion: This is the first study to demonstrate an independent
impact on clinical prognosis by transcription factors acting at spe-
cific promoterelements of an invasion-related gene, and mediating
specific signaling, in colorectal cancer. Such analysis can select
new high-risk subgroups for individualized targeting approaches.
doi:10.1016/j.ejcsup.2006.04.130
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LDH is an intracellular enzyme that reflects important biological
processes such as metabolic state, activation status or malignant
process. The spontaneous LDH release from peripheral blood
lymphocytes (PBL) of patients with breast cancer, lymphoma,
head and neck, and malignant melanoma is associated with
advanced clinical stage, bulky tumor mass, reflecting cell mem-
brane alterations, possible by TNF. As breast cancer is a hor-
mone-dependent tumor, in this study we investigate in vitro,
effect of sex steroid hormone, 17-b estradiol, on membrane char-
acteristics of PBL in 37 breast cancer patients relevant to clinical
stage, menopause, Karnofski index before and undergoing
tamoxifen therapy. We found that 17-b estradiol induced an
increase in spontaneous LDH release activity of PBL at dose and
time dependent manner in healthy controls with no changes in
PBL cell cycle phase distribution (determined by Flow cytometry)
and total intracellular LDH activity (determined from separated
lymphocytes after lysis by ultrasound). Spontaneous LDH release
activity from PBL of breast cancer patients with metastatic dis-
ease, undergoing tamoxifen therapy show significant decrease
of spontaneous LDH release activity compared to untreated
patients. In vitro treatment with 17-b estradiol of PBL had no
effect on increase of spontaneous LDH release activity in breastcancer patients undergoing tamoxifen therapy, contrary to
healthy control PBL. Based on these results we show for the first
time that PBL of breast cancer patients undergoing anti-estrogen
therapy show cell membrane stabilization. We conclude that
determination of spontaneous LDH release activity in breast can-
cer patients is valuable in diagnosis and monitoring of the thera-
peutic effect of standard and anti-estrogen therapy.
doi:10.1016/j.ejcsup.2006.04.131
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Background: Preoperative chemotherapy is increasingly
employed in operable breast cancer. Response or resistance can-
not be predicted and treatment time may be lost if an ineffective
regimen is selected. At our institute, prospective clinical trials
were designed to identify gene expression patterns predicting
response to preoperative chemotherapy in breast cancer patients.
Methods: Patients with operable or locally advanced breast can-
cer were either included in a randomized phase II study or
received neoadjuvant chemotherapy off protocol. Treatment reg-
imens were chosen dependent on the HER2 status of the tumor
and response was evaluated by MRI. From all patients 14G core
needle biopsies were taken before treatment and total RNA was
isolated. Amplified mRNA was labeled and hybridized to 35k
human oligo microarrays from our microarray facility.
Results: From 48 patients good quality RNA from biopsy tissue
with more than 50% tumor cells was isolated. In a training set
containing 11 pathological complete remissions (pCR) and 9
non-responders (NR) we were able to separate these groups by
using 20 genes in a supervised classification with Euclidian dis-
tance and a 9-step cross validation. These results could be vali-
dated in an independent set of 11 samples (6 pCR, 5 NR). From
10 out of 11 samples, response status could be predicted correctly,
independent from the treatment regimen administered. Although
ER-positive tumors have a lower pCR rate than ER-negative ones,
the steroid hormone receptors were not present in the classifier.
Conclusions: Neoadjuvant chemotherapy studies provide a good
setting to identify gene expression profiles associated with response
to specific regimens. Large series of patients (>100) are required to
obtain reliable and reproducible gene expression signatures.
doi:10.1016/j.ejcsup.2006.04.132
